Press-release for stocks related to obesity for NVO

Prices are updated after-hours

tags : Obesity symbols : NVO

save search

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Published: 2024-03-08 (Crawled : 20:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| Email alert Add to watchlist
fda obesity first treatment risk heart

Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| Email alert Add to watchlist
wegovy obesity disease approved risk cardiovascular

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 39.79% | O: 1.88% H: 0.59% C: -0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 35.24% | O: -2.39% H: 0.0% C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 76.74% | O: 6.22% H: 1.26% C: -6.19%
ozempic obesity study

Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity
Published: 2023-09-20 (Crawled : 19:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 29.54% | O: -1.92% H: 0.61% C: -1.74%
obesity initiative global

Semaglutide 2.4 mg shows large reductions in heart failure-related symptoms and physical limitations in people with heart failure with preserved ejection fraction and obesity
Published: 2023-08-25 (Crawled : 10:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 32.41% | O: -0.34% H: 1.29% C: 0.93%
obesity heart

Global Obesity Treatment Market Poised to Reach $26.44 Billion by 2028, Fueled by Rising Prevalence and Innovative Interventions
Published: 2023-08-25 (Crawled : 02:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -28.1% | O: -0.06% H: 1.52% C: 0.66%
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 32.41% | O: -0.34% H: 1.29% C: 0.93%
MDT | $79.48 0.37% -0.29% 6.7M

Health Technology

| -3.46% | O: -0.98% H: 1.19% C: 0.82%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -9.82% | O: 0.51% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 13.07% | O: -0.11% H: 0.44% C: -0.22%
obesity reach treatment global market

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Published: 2023-08-08 (Crawled : 10:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 52.09% | O: 15.34% H: 3.26% C: 1.64%
obesity risk trial cardiovascular

Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Published: 2023-05-22 (Crawled : 15:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| -28.05% | O: -0.04% H: 0.86% C: 0.02%
obesity trial

Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
Published: 2023-04-12 (Crawled : 09:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| -22.52% | O: 1.82% H: 2.28% C: 1.4%
partnership obesity biosystems therapeutics diabetes

The Worldwide Obesity Treatment Industry is Expected to Reach $25+ Billion by 2027
Published: 2022-04-04 (Crawled : 21:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 7.82% | O: 0.57% H: 1.02% C: 0.31%
MDT | $79.48 0.37% -0.29% 6.7M

Health Technology

| -29.17% | O: -1.45% H: 0.0% C: 0.0%
K | News | $57.38 1.49% 0.0% 2.8M

Consumer Non-Durables

| -12.14% | O: -0.4% H: 2.2% C: 1.14%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -16.91% | O: -0.95% H: 0.0% C: 0.0%
BC | $83.94 2.27% 0.0% 890K

Consumer Durables

| 4.27% | O: -1.27% H: 1.16% C: -5.2%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 2.79% | O: 0.0% H: 2.51% C: 0.95%
treatment obesity

Novo Nordisk Brokers Another Deal in Fight Against Obesity
Published: 2022-01-17 (Crawled : 16:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| Email alert Add to watchlist
obesity deal

Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities
Published: 2021-11-11 (Crawled : 17:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 8.87% | O: 0.79% H: 0.0% C: 0.0%
treatment obesity europe approval

Global $5.42 Bn Anti-Obesity Drugs Markets to 2030: Focus on Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies
Published: 2021-08-31 (Crawled : 16:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 19.86% | O: -0.66% H: 0.02% C: -1.7%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -2.84% | O: -0.61% H: 0.52% C: 0.2%
obesity drug

Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions
Published: 2021-06-16 (Crawled : 13:15) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 45.1% | O: -0.2% H: 0.49% C: -0.91%
diabetes obesity research

Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Published: 2021-04-21 (Crawled : 14:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology